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1540Objective: We evaluated whether rheumatic aortic valve disease of mild degree should be treated in patients
undergoing mitral valve surgery.
Methods: From 1992 to 2010, 197 patients (aged 52 [19-82] years, male:female ¼ 60:137) who had rheumatic
mitral valve disease and mild aortic valve disease were enrolled. The aortic valve was untreated in 114 patients
(no treatment group), repaired in 40 patients (aortic valvuloplasty group), and replaced in 43 patients (aortic
valve replacement group).
Results: Operative mortality occurred in 4 patients (2.0%). There were no differences in early mortality and
postoperative complications among the 3 groups. Overall survival at 5, 10, and 15 years was 96.3%, 92.1%,
and 85.7%, respectively. In the no treatment group, progression-free survival in significant aortic valve disease
at 5, 10, and 15 years was 98.7%, 91.3%, and 81.1%, respectively. This was not superior in the aortic
valvuloplasty group (85.9%, 77.6%, and 69.8%, respectively) than in the no treatment group. Freedom from
aortic valve disease was lower in patients with aortic stenosis than in those with aortic regurgitation in univariate
and multivariable analyses (P< .001). Reoperation was performed in 19 patients, including 2 aortic valve
reoperations. Aortic valve–related event-free survival was similar among the 3 groups.
Conclusions: Mild aortic valve disease in patients undergoing rheumatic mitral valve surgery could be left
untreated, because preventive aortic valve operation does not result in better clinical and echocardiographic
outcomes. (J Thorac Cardiovasc Surg 2014;147:1540-6)Aortic valve pathology is frequently found in patients un-
dergoing mitral valve surgery for rheumatic mitral valve
disease. Although current guidelines do not indicate preven-
tive surgery for mild degenerative aortic valve disease
(AVD) during other cardiac surgery, previous studies dem-
onstrated that rheumatic valve disease exhibited a pathology
of both mitral and aortic valves in more than one third of pa-
tients,1-3 and the rheumatic valvulitis tended to involve both
valves in almost all patients during a 20-year follow-up.2,3
However, few studies demonstrated long-term changes of
untreated aortic valve lesions after mitral valve surgery.4-6
In addition, whether treating mild AVD by repair or
replacement is beneficial has not been elucidated. The
aim of this study was to evaluate whether rheumatic AVD
of mild degree should be treated concomitantly at the
time of mitral valve surgery.
MATERIALS AND METHODS
Patient Characteristics
The study protocol was reviewed by the institutional review board
and approved as a minimal risk retrospective study (Approval Number:e Department of Thoracic and Cardiovascular Surgery, Seoul National Uni-
y Hospital, Seoul, Korea.
res: Authors have nothing to disclose with regard to commercial support.
d for publication Feb 18, 2013; revisions received April 21, 2013; accepted
blication May 10, 2013; available ahead of print July 24, 2013.
for reprints: Hyuk Ahn, MD, PhD, Department of Thoracic and Cardiovas-
Surgery, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu,
110-744, Korea (E-mail: ahnhyuk@snu.ac.kr).
23/$36.00
ht  2014 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.05.040
The Journal of Thoracic and Cardiovascular SurH-1204-023-403) that did not require individual consent based on the
institutional guidelines for waiving consent. From January 1992 to De-
cember 2010, 197 patients (52 [19-82] years, male:female ¼ 60:137)
who underwent first-time cardiac surgery for rheumatic mitral valve
disease combined with mild AVD were enrolled in the present study.
Patients exhibiting degenerative pathology were excluded. Patients
were divided into 3 groups: the aortic valve was left untreated (no treat-
ment [NT] group, n ¼ 114) and concomitant aortic valve repair (aortic
valvuloplasty [AVP] group, n ¼ 40) or aortic valve replacement
(AVR group, n ¼ 43). Demographic data of the study patients were
similar among the 3 groups (Table 1). Echocardiographic data showed
that more patients in the AVP and AVR groups had stenotic aortic
valve pathology compared with the NT group (P ¼ .001). However,
the aortic valve area and mean transvalvular pressure gradient
in patients who had stenotic aortic valves were similar among the
3 groups (Table 1).
Surgical Procedures
All operations were performed under a routine aorto-bicaval cannula-
tion, moderate hypothermia, and cold cardioplegic arrest via a median ster-
notomy. Performing aortic valve intervention was at the discretion of the
operating surgeon. The mitral valve was repaired in 18.8% of patients
(37/197). The AVP and NT groups underwent mitral valvuloplasty more
frequently than the AVR group (P ¼ .002). Techniques of aortic valve re-
pair included slicing and decalcification of thickened and calcified aortic
valve leaflets (n ¼ 6), commissurotomy (n ¼ 2), or both (n ¼ 32). In the
43 patients in the AVR group, bileaflet mechanical valves were used in
39 patients and bovine pericardial bioprostheses were inserted in 4 patients.
Concomitant procedures, such as tricuspid valve operation and arrhythmia
surgery, were performed in 81.2% of patients (160/197). A greater number
of patients in the NT group underwent arrhythmia surgery than in the AVR
group (P ¼ .034). The cardiopulmonary bypass and aortic crossclamp
times were 161 (46-309) minutes and 109 (21-231) minutes, respectively.
These were longer in the AVR group than in the NT and AVP groups
(Table 2).gery c May 2014
Abbreviations and Acronyms
AVD ¼ aortic valve disease
AVP ¼ aortic valvuloplasty
AVR ¼ aortic valve replacement
CI ¼ confidence interval
HR ¼ hazard ratio
NT ¼ no treatment
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An initial postoperative echocardiographic evaluation was performed
before discharge in all but 2 patients who died early after surgery.
Follow-up echocardiograms were performed at the discretion of the
operating surgeon or referring physicians during the follow-up. At least 1
echocardiogram was performed in 94% of the survivors (181/193). The
last follow-up echocardiogram was performed at 95 (3-221) months after
the surgery. In patients exhibiting normal left ventricular function, the
mean pressure gradient calculated with the Bernoulli equation by
continuous-wave Doppler echocardiography was used to define the grade
of aortic stenosis (mild,<25 mm Hg; moderate, 25-40 mm Hg; severe,
>40 mm Hg). In patients with left ventricular dysfunction, the aortic valve
area was used to define the severity of aortic stenosis (mild,>1.5 cm2; mod-
erate, 1.0-1.5 cm2; severe,<1.0 cm2). The degree of aortic regurgitation
was graded in accordance with previous guidelines.7-9
Evaluation of Early and Long-Term Clinical
Outcomes
Operative mortality was defined as death within 30 days or during the
same hospitalization period after the surgery. Patients underwent a regular
postoperative follow-up through the outpatient clinic at 3- or 4-month in-
tervals and were contacted by telephone for confirmation of their condition
if the last clinic visit was not conducted at the scheduled time. Follow-up
was completed in 96.4% of the survivors (186/193), with a follow-up du-
ration of 114 (1-242) months. Cardiac death was defined as any death re-
lated to cardiac events, including sudden death during the follow-up.
Aortic valve–related mortality was defined as cardiac death that originated
from aortic valve–related complications or sudden death. Valve-related
complications were recorded according to the previous guidelines.10 Sig-
nificant native AVD was defined as moderate or greater degree of AVD
in the NTand AVP groups. Significant prosthetic AVD included significant
transvalvular pressure gradient (mean transvalvular gradient 25 mm Hg)
across the prosthetic aortic valve and moderate or greater degree of aortic
regurgitation of the bioprosthetic valve in the AVR group. Aortic valve–re-
lated events include the following: (1) aortic valve–related mortality,
including sudden death; (2) composite of thrombosis, embolism, and bleed-
ing; (3) significant native or prosthetic AVD; (4) subsequent aortic valve
operation; and (5) native or prosthetic aortic valve endocarditis.
Statistical Analysis
Statistical analyses were performed with SPSS version 12 (SPSS Inc,
Chicago, Ill) and SAS version 9.1 (SAS Institute Inc, Cary, NC). Data
were expressed as mean standard deviation, median with ranges, or pro-
portions. Comparison among the 3 groups was performed with the chi-
square test or the Fisher exact test for categoric variables and analysis of
variance test for continuous variables. Post hoc comparison was performed
using the Bonferroni method. Survival was estimated using the Kaplan–
Meier method, and comparisons among groups were performed with the
log-rank test or Cox regression analysis. The Cox proportional hazard
model was adopted for analysis of risk factors for time-related events.The Journal of Thoracic and CarThe proportional hazard property was tested using the restricted cubic
spline for continuous variables and the Cox proportional hazards model
with an interaction term with time for categoric variables.11,12 All
independent variables in the Cox regressions met the proportional
hazards assumption. Multicollinearity was controlled using backward
stepwise regression. Variables with a P value of less than .2 were entered
into multivariable analyses.
RESULTS
Early Clinical and Echocardiographic Results
The operative mortality rate was 2.0% (4/197 patients).
Postoperative morbidities included low cardiac output
syndrome (n¼ 11, 5.6%), postoperative bleeding requiring
reoperation (n ¼ 6, 3.0%), stroke (n ¼ 3, 1.5%), and acute
renal failure (n ¼ 3, 1.5%). There were no differences in
operative mortality and postoperative complications among
the 3 groups (Table 3). Postoperative echocardiography was
performed at 8 4 days after the surgery in all but 2 patients
(1 patient in the NT group and 1 patient in the AVR group).
In the 113 patients in the NT group who underwent postop-
erative echocardiography, the grade of the aortic valve
lesion improved to less than mild degree (mean pressure
gradient<10 mm Hg and no significant regurgitation jet)
in 16 patients (14.2%), remained the same in 96 patients
(85.0%), and became aggravated to moderate degree in 1
patient (0.9%). In the AVP group, more patients had
improved AVD compared with the NT group (P ¼ .006);
the degree of AVD improved in 15 patients (37.5%),
remained the same in 24 patients (60%), and became
aggravated in 1 patient (2.5%). In the AVR group, early
complications associated with AVR, such as prosthetic
valve endocarditis, paravalvular leak, and significant trans-
valvular pressure gradient, were not found.
Long-Term Clinical Outcomes
Among the 193 survivors, late death occurred in 12 pa-
tients, including 4 cardiac deaths. Causes in cardiac death
were heart failure associated with tricuspid regurgitation
(n ¼ 2), prosthetic mitral valve failure (n ¼ 1), and sudden
death (n ¼ 1).
The overall survival at 5, 10, and 15 years was 96.3%,
92.1%, and 85.7%, respectively. Survival in cardiac death
at 5, 10, and 15 years was 97.9%, 96.0%, and 94.9%, re-
spectively. There were no differences in the overall survival
and survival in cardiac death among the 3 groups (P¼ .401
and .633, respectively). Age-adjusted multivariable analysis
revealed that hypertension and combined tricuspid valve
disease were risk factors for the overall survival (P ¼ .001
and .025, respectively). Hypertension was also a significant
risk factor for long-term cardiac death (P ¼ .002, Table 4).
Progression of Native Aortic Valve Disease in the No
Treatment and Aortic Valve Repair Groups
In the NT group, significant AVD occurred in 8 patients.
Progression-free survival in significant AVD at 5, 10, and 15diovascular Surgery c Volume 147, Number 5 1541
TABLE 1. Preoperative characteristics and echocardiographic data of study patients
Total (n ¼ 197) NT group (n ¼ 114) AVP group (n ¼ 40) AVR group (n ¼ 43) P value
Age (y) 52 (19-82) 54 (24-82) 52 (25-76) 49 (19-71) .183
Male/female 60/137 30/84 11/29 19/24 .086
Body surface area (m2) 1.56  0.15 1.54  0.15 1.56  0.17 1.60  0.13 .096
Risk factors, n (%)
Smoking 30 (15.2%) 18 (15.8%) 5 (12.5%) 7 (16.3%) .863
Hypertension 10 (5.1%) 4 (3.5%) 1 (2.5%) 5 (11.6%) .760
Diabetes mellitus 11 (5.6%) 8 (7.0%) 1 (2.5%) 2 (4.7%) .267
Overweight (BMI 25 kg/m2) 24 (12.2%) 13 (11.4%) 6 (15.0%) 5 (11.6%) .584
History of stroke 32 (16.2%) 19 (16.7%) 8 (20.0%) 5 (11.6%) .576
NYHA class 3 78 (39.6%) 48 (42.1%) 17 (42.5%) 13 (30.2%) .365
Atrial fibrillation 172 (87.3%) 97 (85.1%) 34 (85.0%) 41 (95.3%) .201
Echocardiographic data
LVEF (%) 54.9  9.3 54.5  9.2 55.3  8.2 55.6  10.9 .754
Left atrial size (mm) 60.9  14.9 62.4  16.9 58.3  10.8 59.6  12.4 .284
Systolic PAP (mm Hg) 47.1  16.7 49.5  17.6 45.3  16.6 42.0  13.0 .065
Data of patients with AS
No. of patients (%) 30 (15.2%) 8 (7.0%) 11 (27.5%) 11 (25.6%) .001
AVA (cm2) 1.55  0.29 1.57  0.16 1.55  0.34 1.52  0.41 .977
Mean PG (mm Hg) 15.4  4.3 14.4  2.2 16.2  5.1 16.2  5.1 .699
AS, Aortic stenosis; AVA, aortic valve area; AVP, aortic valvuloplasty; AVR, aortic valve replacement; BMI, body mass index; LVEF, left ventricular ejection fraction; NT, no
treatment; NYHA, New York Heart Association; PAP, pulmonary artery pressure; PG, pressure gradient.
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AVP group, significant AVD occurred in 8 patients.
Progression-free survival in significant AVD at 5, 10, and
15 years was 85.9%, 77.6%, and 69.8%, respectively. A
univariate analysis revealed that the progression-free
survival in significant AVD was lower in the AVP group
than in the NT group (P ¼ .027). However, this difference
disappeared in the multivariable Cox proportional hazard
analysis (P ¼ .569, Figure 1).Progression of Prosthetic Aortic Valve Disease
In the AVR group, a significant transvalvular pressure
gradient was found in 7 patients who had mechanical aortic
valves, even though the opening of the prosthetic valve
leaflets was not restricted. In those patients, the estimated
effective orifice area index presented by manufacturers
was greater than 0.9 cm2/m2, and mean transvalvularTABLE 2. Operative data of the study patients
Total (n ¼ 197) NT group (n ¼ 1
Mitral valve surgery, n (%)
Mitral valve repair 37 (18.8%) 23 (20.2%)*
Mitral valve replacement 160 (81.2%) 91 (79.8%)
Concomitant procedures, n (%) 160 (81.2%) 96 (84.2%)
Tricuspid valve surgery 68 (34.5%) 38 (33.3%)
Arrhythmia surgery 112 (56.9%) 71 (62.3%)*
Others 3 (1.5%) 2 (1.8%)
CPB time (min) 161 (46-309) 153 (46-277)*
ACC time (min) 109 (21-231) 100 (21-209)*,
ACC, Aortic crossclamp; AVP, aortic valvuloplasty; AVR, aortic valve replacement; CPB, c
pared with the AVR group in post hoc comparison. yVariable with significant difference c
1542 The Journal of Thoracic and Cardiovascular Surpressure gradients ranged from 8 to 18 mm Hg at the early
postoperative echocardiograms. No patient had moderate or
greater degree of prosthetic valve regurgitation. Freedom
from significant AVD at 5, 10, and 15 years was 90.4%,
85.9%, and 76.0%, respectively. The AVD-free survival
in the AVR group was between that in the NT and AVP
groups without statistically significant difference compared
with the other 2 groups (Figure 2).Progression of Aortic Valve Disease According to
Type of Aortic Valve Lesion
In 30 patients who had aortic stenosis, 1 patient in the NT
group died early after surgery. Significant AVD occurred in
12 of the 29 survivors (3/7 patients in the NT group,
5/11 patients in the AVP group, and 4/11 patients in the
AVR group). Five-, 10-, and 15-year freedom rates from
significant AVD in patients with aortic stenosis were14) AVP group (n ¼ 40) AVR group (n ¼ 43) P value
13 (32.5%)* 1 (2.3%) .002
27 (67.5%) 42 (97.7%)
35 (87.5%) 29 (67.4%)
14 (35.0%) 16 (37.2%) .899
24 (60.0%) 17 (39.5%) .034
1 (2.5%) 0 (0%) .927
166 (116-300) 195 (86-309) <.001
y 122 (75-201) 150 (61-231) <.001
ardiopulmonary bypass; NT, no treatment. *Variables with significant difference com-
ompared with the AVP group in post hoc comparison.
gery c May 2014
TABLE 3. Operative mortality and postoperative complications
Total (n ¼ 197) NT group (n ¼ 114) AVP group (n ¼ 40) AVR group (n ¼ 43) P value
Mortality, n (%) 4 (2.0%) 3 (2.6%) 0 (0%) 1 (2.3%) .730
Morbidities, n (%)
LCOS 11 (5.6%) 7 (6.1%) 1 (2.5%) 3 (7.0%) .989
New-onset atrial fibrillation 6 (3.0%) 3 (2.6%) 3 (7.5%) 0 (0%) .671
Bleeding reoperation 6 (3.0%) 3 (2.6%) 1 (2.5%) 2 (4.7%) .555
IABP insertion 5 (2.5%) 3 (2.6%) 1 (2.5%) 1 (2.3%) .913
Respiratory complication 3 (1.5%) 1 (0.9%) 1 (2.5%) 1 (2.3%) .442
Stroke 3 (1.5%) 2 (1.8%) 0 (0%) 1 (2.3%) .954
Acute renal failure 3 (1.5%) 3 (2.6%) 0 (0%) 0 (0%) .173
Mediastinitis 1 (0.5%) 1 (0.9%) 0 (0%) 0 (0%) .434
AVP, Aortic valvuloplasty; AVR, aortic valve replacement; IABP, intra-aortic balloon pump; LCOS, low cardiac output syndrome; NT, no treatment.
Hwang et al Acquired Cardiovascular Disease
A
C
D80.4%, 56.6%, and 32.4%, respectively, without inter-
group difference (P ¼ .963).
In 167 patients who had aortic regurgitation, early mor-
tality occurred in 3 patients (2 in the NT group and 1 in
the AVR group). During the follow-up, significant AVD
occurred in 11 of the 164 survivors (5/104 patients in the
NT group, 3/29 patients in AVP group, and 3/31 patients
in the AVR group). Five-, 10-, and 15-year freedom rates
from significant AVD in patients with aortic regurgitation
were 96.9%, 94.5%, and 86.4%, respectively.
Freedom from significant AVDwas lower in patients with
aortic stenosis than in those with aortic regurgitation in
univariate (P < .001) and multicollinearity-controlled
multivariable analyses (P < .001; hazard ratio [HR],
7.533; 95% confidence interval [CI], 3.273-17.335)
(Table 5; Figures 3 and 4). When subgroup analyses were
performed separately in each group, stenotic aortic valve
pathology remained the only significant predictor for
aggravation of untreated aortic valve (P ¼ .001; HR,
9.736; 95% CI, 2.399-39.510) and repaired aortic valve
(P ¼ .050; HR, 4.212; 95% CI, 1.001-17.728). In
the AVR group, however, there was no statistically
significant risk factor associated with the progression of
prosthetic AVD.Long-Term Aortic Valve–Related Events
Subsequent aortic valve operation was performed in only
2 patients. One patient in the NT group underwent AVR 9TABLE 4. Multivariable risk factor analysis for overall survival and
survival in cardiac death
Risk factors for overall mortality Hazard ratio (95% CI) P value
Age (y) 1.107 (1.053-1.164) <.001
Hypertension 8.149 (2.372-27.999) .001
Concomitant TR surgery 3.570 (1.178-10.816) .025
Risk factors for cardiac death Hazard ratio (95% CI) P value
Age (y) 1.093 (1.017-1.174) .016
Hypertension 11.613 (2.484-54.296) .002
CI, Confidence interval; TR, tricuspid regurgitation.
The Journal of Thoracic and Caryears after the index operation. The primary indication of
reoperation was severe tricuspid valve regurgitation. Intra-
operative findings revealed retracted aortic valve cusp,
and it was replaced to prevent future reoperation, although
the grade of AVD remained mild. The other patient in the
AVR group underwent aortic valve re-replacement because
the subaortic pannus was causing severe transvalvular pres-
sure gradient 16 years after the surgery. Another 17 patients
underwent cardiac reoperations other than aortic valve sur-
gery during the follow-up period. Mitral valve surgery was
performed in 12 patients (redo-mitral valve replacement in
7 patients, mitral valve replacement after initial mitral valve
repair in 4 patients, and mitral valve re-repair in 1 patient),
and a tricuspid valve operation was performed in 8 patients
for severe tricuspid regurgitation, including 2 patients who
underwent tricuspid annuloplasty at the initial operation.
Three patients underwent both mitral and tricuspid valve
surgery.FIGURE 1. Risk factor–adjusted curve by Cox proportional hazard model
for freedom from progression of AVD in the NT and AVP groups. AVD,
Aortic valve disease; AVP, aortic valvuloplasty; NT, no treatment.
diovascular Surgery c Volume 147, Number 5 1543
FIGURE 2. Freedom from progression of native and prosthetic AVD. Post
hoc comparison revealed no significant difference in freedom from pro-
gression of AVD between the AVR group and the NT and AVP groups.
AVD, Aortic valve disease; AVP, aortic valvuloplasty; AVR, aortic valve re-
placement; NT, no treatment.
FIGURE 3. Risk factor–adjusted curve by Cox proportional hazard model
for freedom from progression of AVD according to aortic valve pathology;
patients with AS versus patients with AR.AR, Aortic regurgitation;AS, aor-
tic stenosis; AVD, aortic valve disease.
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tients required readmission to control congestive heart fail-
ure, these were not related to the AVD. Aortic valve–related
event-free survival at 5, 10, and 15 years was 94.2%,
87.3%, and 79.6%, respectively, without intergroup differ-
ence (P ¼ .154, Figure 5).DISCUSSION
This study demonstrated 3 main findings. First, mild
rheumatic aortic stenosis frequently progresses in patients
undergoing rheumatic mitral valve surgery, regardless of
initial treatment strategy. Second, mild aortic valve regurgi-
tation in patients undergoing rheumatic mitral valve surgery
rarely progresses up to 20 years after the surgery. Third,
concomitant aortic valve intervention, including conserva-
tive valve repair and replacement, does not result in better
outcomes in terms of freedom from significant AVD, re-
gardless of the type of aortic valve lesion.TABLE 5. Multivariable risk factor analysis for progression of aortic
valve disease in the no treatment and aortic valvuloplasty groups
Variables
Univariate
analysis Multivariable analysis
P value
Hazard ratio
(95% CI) P value
Repair of the aortic valve .032 — NS
Female sex .130 — NS
Body surface area, m2 .052 — NS
Stenotic aortic valve <.001 5.645 (1.717-18.556) .004
Arrhythmia surgery .185 — NS
CI, Confidence interval; NS, not significant.
1544 The Journal of Thoracic and Cardiovascular SurCombined AVD is a frequently found pathology in up to
one third of patients with rheumatic mitral valve disease.1-3
Although previous studies demonstrated that rheumatic
valve disease involved both aortic and mitral valves in
almost all patients during a 20-year follow-up,2,3 fewFIGURE 4. Survival curves for freedom from progression of AVD ac-
cording to treatment strategy (NT, AVP, and AVR groups) and aortic valve
pathology (AS and AR). AR, Aortic regurgitation; AS, aortic stenosis; AVD,
aortic valve disease; AVP, aortic valvuloplasty; AVR, aortic valve replace-
ment; NT, no treatment.
gery c May 2014
FIGURE 5. Freedom from aortic valve–related event in the NT, AVP, and
AVR groups. AVP, Aortic valvuloplasty; AVR, aortic valve replacement;
AVRE, aortic valve–related event; NT, no treatment.
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mitral valve surgery.4-6 Another issue is the efficacy of aortic
valve repair in such a patient population. Few studies have
demonstrated the results of aortic valve repair in patients
with predominant rheumatic mitral valve disease.13,14
A previous study demonstrated that freedom from
reoperation after aortic valve repair for mild-to-moderate
AVD was 75% at 13 years after surgery.13 The authors sug-
gested that aortic valve repair could be applied successfully
in mild-to-moderate rheumatic AVD accompanying a pre-
dominant mitral lesion. However, another study demon-
strated that conservative operations for rheumatic AVD
did not seem appropriate because the freedom from reoper-
ation of the aortic valvewas only 25.3% at a 22-year follow-
up period after surgery.14 The authors suggested that if an
adequate mitral valve repair was achieved, an attitude to-
ward ignoring the aortic lesion might be adopted.14
Although there have been reports demonstrating the
changes in AVD after mitral valve surgery for rheumatic mi-
tral valve disease, no study has directly compared the clin-
ical outcomes based on the treatment strategy for combined
AVD. In the present study, we compared long-term clinical
outcomes and echocardiographic results after surgery for
rheumatic mitral valve disease, according to the treatment
strategies for combined AVD. The addition of aortic valve
repair or replacement for mild AVD did not affect the early
clinical outcomes, although patients in the AVR group un-
derwent a longer operation with lengthier cardiopulmonary
bypass and aortic crossclamp times than the other 2 groups.
Also, the long-term survival and freedom from cardiac
death were not different among the groups. TheThe Journal of Thoracic and Carmultivariable analysis revealed that hypertension and com-
bined tricuspid valve surgery were associated with the long-
term mortality, perhaps because 68 patients who underwent
concomitant tricuspid valve surgery were sicker than the
others, were significantly older (55 [34-81] years vs 49
[19-82] years), and more frequently had diabetes (7/68 pa-
tients vs 4/125 patients). However, we did not describe de-
tailed data on this issue because they were beyond the scope
of the present study.
Up to 20 years follow-up after the surgery, untreated
aortic regurgitation rarely progressed to moderate or higher
grades, regardless of the initial treatment option. On the
contrary, aortic stenosis frequently progressed to moderate
or more degree. These results are in agreement with a previ-
ous study that showed the progression of native AVD in
patients with aortic stenosis.5,15 In addition, we compared
the changes of an aortic valve that was left untreated with
those of a repaired aortic valve. Conservative aortic valve
repair for both aortic stenosis and regurgitation did not
reduce the occurrence of significant AVD and aortic
valve–related events during the follow-up period, even
though patients in the AVP group experienced an improved
degree of AVD early after surgery. Although there are more
aggressive techniques to repair the aortic valve with favor-
able long-term results, it is doubtful whether those should
be applied to mild aortic valve lesions.16,17 Likewise,
although patients in the AVR group did not have aortic
valve–related complications early after the surgery, AVR
did not result in better aortic valve–related event-free
survivals for up to 20 years of follow-up. In 7 patients, trans-
valvular pressure gradient increased during the follow-up.
In those patients, the effective orifice area index was appro-
priate and the mean transvalvular pressure gradient was in-
significant at the early postoperative period. Formation of
a subaortic pannus, which is a frequently found nonstruc-
tural valve dysfunction after AVR, might be the main reason
for the increased transvalvular pressure gradient, because
echocardiographic findings confirmed that the opening of
the prosthetic valve cusps was not restricted.
Study Limitations
First, the present study was a retrospective observational
study at a single institution. Second, selection bias of the ret-
rospective studymight affect the results of the present study,
although all patients in the 3 groups had mild AVD, and aor-
tic valve area and mean pressure gradient in patients with
stenotic aortic valve lesion were similar among the 3 groups.
Third, the numbers of patients in the AVP and AVR groups
might be relatively small to achieve statistically significant
differences and draw a definite conclusion. Fourth, general-
ization of our results to young patients in developing
countries may be limited, because the old age of the study
patients was a characteristic of the rheumatic patients with
a stabilized disease process in developed countries.diovascular Surgery c Volume 147, Number 5 1545
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When patients undergoing rheumatic mitral valve sur-
gery have a mild degree of AVD, the aortic valve can be
left untreated regardless of the type of aortic valve lesion,
because conservative valve repair and valve replacement
do not improve the long-term clinical outcomes. However,
echocardiographic follow-up might be necessary in patients
with stenotic AVD, because it tends to progress more easily
than regurgitant AVD.
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